Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rationale for combining acamprosate and naltrexone for treating alcohol dependence.

Barbara J Mason1

  • 1Department of Neuropharmacology, The Scripps Research Institute, 10550 North Torrey Pines Road, TPC5, La Jolla, California 92037, USA. mason@scripps.edu

Journal of Studies on Alcohol. Supplement
|October 15, 2005
PubMed
Summary

Acamprosate and naltrexone, used for alcohol dependence treatment, show promise when combined. Further large-scale trials are recommended to confirm efficacy and safety of this combination therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Predictive Value of Plasma Bioactive Lipids on Craving in Human Volunteers With Alcohol Use Disorder.

Biological psychiatry global open science·2024
Same author

George Robert Siggins: Researcher, musician, surfer, mentor, and friend.

Alcohol, clinical & experimental research·2024
Same author

A reverse translational study of PPAR-α agonist efficacy in human and rodent models relevant to alcohol use disorder.

Neurobiology of stress·2024
Same author

Suvorexant, an FDA-approved dual orexin receptor antagonist, reduces oxycodone self-administration and conditioned reinstatement in male and female rats.

Frontiers in pharmacology·2023
Same author

Preclinical and clinical evidence for suppression of alcohol intake by apremilast.

The Journal of clinical investigation·2023
Same author

Alternative use of suvorexant (Belsomra<sup>®</sup>) for the prevention of alcohol drinking and seeking in rats with a history of alcohol dependence.

Frontiers in behavioral neuroscience·2023

Area of Science:

  • Pharmacology
  • Clinical Medicine
  • Addiction Science

Background:

  • Acamprosate and naltrexone are FDA-approved medications for alcohol dependence.
  • Both drugs have distinct pharmacological profiles and are generally well-tolerated.
  • There is growing interest in their combined use for enhanced treatment outcomes.

Purpose of the Study:

  • To review the evidence for acamprosate and naltrexone, alone and in combination.
  • To compare their efficacy, safety, and pharmacokinetic/pharmacodynamic interactions.
  • To evaluate their potential for treating alcohol dependence.

Main Methods:

  • Review of published double-blind, placebo-controlled trials.
  • Analysis of pharmacokinetic and pharmacodynamic drug interaction studies.

Related Experiment Videos

  • Examination of a clinical trial combining acamprosate and naltrexone.

    • Main Results:

    • Combination therapy did not significantly increase adverse events.
    • Naltrexone co-administration may increase acamprosate plasma levels, potentially enhancing clinical benefits.
    • Pharmacokinetic and pharmacodynamic studies showed no significant adverse interactions.

    Conclusions:

    • Combining acamprosate and naltrexone warrants further investigation for alcohol dependence treatment.
    • Large-scale, multisite trials are needed to confirm efficacy and safety.
    • Identifying predictors of response to monotherapy and combination therapy is crucial.